000280969 001__ 280969
000280969 005__ 20250921002016.0
000280969 0247_ $$2doi$$a10.1016/j.neurobiolaging.2025.06.006
000280969 0247_ $$2pmid$$apmid:40582243
000280969 0247_ $$2ISSN$$a0197-4580
000280969 0247_ $$2ISSN$$a1558-1497
000280969 0247_ $$2altmetric$$aaltmetric:178234438
000280969 037__ $$aDZNE-2025-01051
000280969 041__ $$aEnglish
000280969 082__ $$a610
000280969 1001_ $$aAkradi, Mohammad$$b0
000280969 245__ $$aHow is self-reported sleep-disordered breathing linked with biomarkers of Alzheimer's disease?
000280969 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000280969 3367_ $$2DRIVER$$aarticle
000280969 3367_ $$2DataCite$$aOutput Types/Journal article
000280969 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756890705_1280
000280969 3367_ $$2BibTeX$$aARTICLE
000280969 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280969 3367_ $$00$$2EndNote$$aJournal Article
000280969 520__ $$aSleep-disordered breathing (SDB) is prevalent in Alzheimer's disease (AD). Here, we assessed how self-reported SDB is linked with AD biomarkers, including amyloid-beta plaque burden (Aβ), regional fluorodeoxyglucose uptake (rFDG-PET), grey matter volume (GMV), cognitive scores, and cerebrospinal fluid (CSF) biomarkers. We selected 757 individuals, including AD, mild cognitive impairment (MCI), and cognitively unimpaired (CU) groups, and divided them according to self-reported SDB condition. Using a stratified subsampling approach, we selected 512 matched subsamples, and effect sizes (ES) of the group-SDB interaction were computed for each biomarker and cognitive score across subsamples. Linear regression assessed associations between the ES of Aβ, rFDG, and GMV with the ES of cognitive scores and CSF biomarkers. The group-SDB interaction had a medium-sized effect on Aβ, rFDG, and GMV biomarkers in several brain areas. Participants with SDB exhibited reduced Aβ burden and increased rFDG uptake in the CU and MCI groups, whereas the AD group showed elevated Aβ burden and decreased rFDG. Additionally, SDB+ individuals demonstrated GMV alterations across all groups. The ES of group-SDB interaction on Aβ in the precuneus, middle temporal gyrus, and fusiform gyrus was associated with the ES of cognitive scores. Taken together, we observed a robust association of SDB with Aβ pathology in PET and CSF relative to rFDG and GMV in the AD group, which was also associated with cognitive decline.
000280969 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280969 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280969 650_7 $$2Other$$aAlzheimer’s disease
000280969 650_7 $$2Other$$aAmyloid-beta
000280969 650_7 $$2Other$$aFluorodeoxyglucose imaging
000280969 650_7 $$2Other$$aGrey matter volume
000280969 650_7 $$2Other$$aSleep-disordered breathing
000280969 7001_ $$aFarzane-Daghigh, Tara$$b1
000280969 7001_ $$aEbneabbasi, Amir$$b2
000280969 7001_ $$aBi, Hanwen$$b3
000280969 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b4$$udzne
000280969 7001_ $$aMander, Bryce A$$b5
000280969 7001_ $$aEickhoff, Simon B$$b6
000280969 7001_ $$aTahmasian, Masoud$$b7
000280969 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b8$$eCollaboration Author
000280969 773__ $$0PERI:(DE-600)1498414-3$$a10.1016/j.neurobiolaging.2025.06.006$$gVol. 154, p. 16 - 24$$p16 - 24$$tNeurobiology of aging$$v154$$x0197-4580$$y2025
000280969 8564_ $$uhttps://pub.dzne.de/record/280969/files/DZNE-2025-01051.pdf$$yOpenAccess
000280969 8564_ $$uhttps://pub.dzne.de/record/280969/files/DZNE-2025-01051%20SUP.docx
000280969 8564_ $$uhttps://pub.dzne.de/record/280969/files/DZNE-2025-01051.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280969 909CO $$ooai:pub.dzne.de:280969$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280969 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000280969 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280969 9141_ $$y2025
000280969 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL AGING : 2022$$d2024-12-13
000280969 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000280969 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280969 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000280969 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000280969 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000280969 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000280969 980__ $$ajournal
000280969 980__ $$aVDB
000280969 980__ $$aUNRESTRICTED
000280969 980__ $$aI:(DE-2719)1011202
000280969 9801_ $$aFullTexts